Introduction
============

MutL homolog 1 (*MLH1*), a constituent gene in the mismatch repair pathway, carries germline mutations in individuals with Lynch syndrome, also termed hereditary non-polyposis colorectal cancer (HNPCC). The gene is reported to acquire 300 different germline mutations, which in addition to mutations in other genes involved in mismatch repair pathway, mainly mutS homolog 2 (*MSH2*), predispose individuals to the disease ([@b1-ol-09-01-0183]). MLH1, a key protein of the mismatch repair process, contains interaction domains for MutS homologs, including MSH2, MSH3 and MSH6, postmeiotic segregation increased 2 (PMS2), MLH3 and PMS1([@b2-ol-09-01-0183]). The heterodimers formed by MLH1 recruit proteins for the excision and repair synthesis.

The germline mutations in *MLH1* in HNPCC include nucleotide substitutions, which result in missense, nonsense or splicing errors and also comprise insertions/deletions. A number of founder mutations, which account for a high proportion of mutations in families with HNPCC, which have been reported in patients with Lynch syndrome ([@b3-ol-09-01-0183]). In addition, certain non-pathogenic mutations in exons and introns of the gene have also been reported ([@b4-ol-09-01-0183],[@b5-ol-09-01-0183]). The *MLH1* gene is highly polymorphic, with \>1,600 variants reported to date (<http://genecards.org/cgi-bin/carddisp.pl?gene=MLH1&search=mlh1%23snp>).

In this study, a novel germline mutation in *MLH1* in a patient with sporadic colorectal cancer (CRC) is reported, which was detected during the whole genome mutational screening. In addition, a total of 1,095 sporadic CRC patients and 1,469 controls were tested for the detected mutation.

Materials and methods
=====================

Study population
----------------

This study included a group of 104 newly diagnosed CRC patients with DNA extracted from their tumor tissues, adjacent healthy mucosa and peripheral blood tissues. A replication group included 1,095 CRC patients and 1,469 controls from whom DNA was extracted from peripheral blood lymphocytes. The information regarding the CRC cases and controls included in the replication group is shown in [Table I](#tI-ol-09-01-0183){ref-type="table"} and has been described previously ([@b6-ol-09-01-0183],[@b7-ol-09-01-0183]). Patients included in this study attended the General University Hospital (Prague, Czech Republic), Thomayer Hospital (Prague, Czech Republic), Central Military Hospital (Prague, Czech Republic), Faculty Hospital (Brno, Czech Republic), Regional Hospital Benesov (Benesov, Czech Republic), Regional Hospital Liberec (Liberec, Czech Republic), Hospital Na Plesi (Nova Ves pod Plesi, Czech Republic), Regional Hospital Pribram (Pribram, Czech Republic), Masaryk Regional Hospital (Ústí nad Labem, Czech Republic), Tomas Bata Regional Hospital (Zlín, Czech Republic) or Jihlava Regional Hospital (Jihlava, Czech Republic). This study was approved by the ethics commitee of the General University Hospital in Prague (Prague, Czech Republic) and written informed consent was obtained from all patients.

Mutation screening in CRC patients
----------------------------------

DNA from tumor tissues, healthy mucosa and blood tissues was extracted using QIAamp DNA Mini Kit and QIAcube (Qiagen, Hilden, Germany). The extracted DNA of the 104 newly diagnosed CRC patients were subjected to mutation detection by high-resolution melting (HRM) using LightCycler® and a 480 High Resolution Melting Master® kit (Roche Diagnostics GmbH, Mannheim, Germany). Polymerase chain reaction amplicons were designed to scan the *MLH1* gene using HRM analysis. All 19 exons in the *MLH1* gene were screened. The region containing exon 2 was amplified using primers with the following sequence: Forward, 5′-AGTTTGTTATCATTGCTTGGCTCAT-3′ and reverse, 5′-TCCAGAACAGAGAAAGGTCCTGACT-3′ ([@b8-ol-09-01-0183]). The 10-μl reaction mixture contained 20 ng genomic DNA, 0.4 mM of each primer and 3 mM MgCl~2~. The reaction conditions were as follows: Activation step at 95°C for 10 min followed by 45 cycles of 95°C for 15 sec, 60°C for 15 sec, 72°C for 25 sec and 72°C for 7 min. Samples with positive HRM signals were further analyzed by sequencing. Sequencing reactions were carried out in a total volume of 10 μl containing 2 μl Big Dye^®^ Terminator v1.1 Cycle Sequencing kit (Applied Biosystems, Life Technologies, Foster City, CA, USA), 2.4 μl H~2~O, 0.3 μl DNA template and 0.3 μl of one primer. The reaction products were purified by ethanol precipitation and sequenced by automated sequencing (Applied Biosystems^®^ 3130 Genetic Analyzer; Applied Biosystems, Life Technologies). The reference sequence of the *MLH1* gene (NG_007109.1) was obtained from the National Center for Biotechnology Information database (<http://www.ncbi.nlm.nih.gov/nuccore/NG_007109.1?from=4863&to=62359&report=genbank>).

Genotyping of the replication group
-----------------------------------

DNA samples from the replication group were genotyped for the novel germ-line variant. The DNA samples from CRC patients and controls were analyzed at the K Bio Science facility (K Bio Science UK Ltd., Hoddesdon, UK) (protocol available at <http://www.kbioscience.co.uk/reagents/KASP_manual.pdf>) under conditions described previously ([@b6-ol-09-01-0183]).

Results
=======

In the initial group, 1/104 sporadic CRC patients exhibited a single nucleotide variant at codon 204 within exon 2 of *MLH1* in tumor tissue and mucosa, as well as in blood lymphocytes DNA. A change of the base C to G resulted in Ile68Met change in the amino acid residue ([Fig. 1](#f1-ol-09-01-0183){ref-type="fig"}). The carrier of the newly identified variant was a 59 year old female with rectal cancer (T3N0M0 stage). Although the family history of the patient was unavailable, the patient had been treated for schizophrenia for 15 years. The tumor was microsatellite-stable, the CpG sites on the *MLH1* promoter were not methylated and the expression of MLH1 protein was not altered in the tumor, when compared with the adjacent mucosa (data not shown). Genotyping of the replication revealed that there were no carriers of the newly identified variant Ile68Met in the CRC or control groups.

Discussion
==========

In this study, a unique variant c. 204 C\>G, p. Ile68Met in exon 2 of the *MLH1* gene was identified in a patient with sporadic CRC. The mutation was germline and was also detectable in the DNA of tumor tissue, colon mucosal tissue and DNA of the peripheral lymphocytes of the patient. Predictive algorithms SIFT ([@b9-ol-09-01-0183]) and PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) indicated that the amino acid change from isoleucin to methionin may influence the functionality of the MLH1 protein. A 3D model of the MLH1 protein demonstrated that amino acid residue 68 isoleucin is located within the enzymatic core that interacts with ATP molecules (<http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=90223>). Therefore, a substitution by methionine may decrease MLH1 activity. Similarly, a variant in an HNPCC patient at the position c.203 T\>A, p. Ile68Asn was previously shown to be deleterious ([@b10-ol-09-01-0183]). Furthermore, a homologous substitution in yeast was found to cause loss of function in a mismatch repair assay ([@b11-ol-09-01-0183]).

The identification of a novel germline variant in *MLH1* with putative impact on the protein function is of significant importance in CRC. *MLH1* is the most frequently mutated gene in HNPCC and is also often altered in sporadic forms ([@b12-ol-09-01-0183]). The novel variant in *MLH1* gene presents a rare event in sporadic CRC, which was identified in 1/1,199 patients. The effect of the mutation, whether a causal germline variant or a rare polymorphism, remains to be determined. Due to the patient history, an association between the novel mutation and mental illness must not be excluded. Neurodegenerative diseases, such as Huntington's disease, are also known to exhibit alterations in mismatch repair genes ([@b13-ol-09-01-0183]).

In conclusion, in the present study a novel *MLH1* mutation was detected in a patient with sporadic CRC. The functionality of the novel c. 204 C\>G, p.Ile68Met variant in exon 2 of *MLH1* gene remains to be determined experimentally, along with its occurrence and relevance in other cancer types.
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![HRM analysis and DNA sequencing of exon 2 of the *MLH1* gene. (A) Diagram of the MLH1 protein in scale. Numbers inside the blue boxes indicate the numbers of exons from which each part of the protein is translated. The three yellow boxes inside represent the ATPase domain, the MutS homolog interaction domain and the PMS2/MLH3/PMS1 interaction domain. A new germ-line variant in exon 2 is located at position c. 204 C\>G, p. Ile68Met, corresponding to the gene region coding a part of ATPase domain of MLH1 protein. The position c. 204 is shown by the black arrow. (B) HRM analysis of exon 2 in tumor DNA samples. The difference plot chart shows relativity between DNA melting temperature and relative intensity of emitted fluorescence. Each curve represents the melting of one DNA sample. The DNA sample bearing the novel gene variant exhibits a different melting profile, which is highlighted by the red color in comparison with the blue-colored melting profiles of wild-type DNA samples. This discrepancy of different melting curves is caused by nucleotide change in the analyzed DNA sequence. The red curve represents the melting of the DNA sample which bears the newly identified variant, c. 204 C\>G, p. Ile68Met, in tumor tissue. To verify the possible germ-line origin of the variant, HRM was performed in healthy tissue and peripheral blood DNA samples. Both samples were positive for the same variant (data not shown). (C) Comparison of DNA sequencing plots of three different DNA samples obtained from the same patient bearing new heterozygous germ-line gene variant c. 204 C\>G, p. Ile68Met. 1, tumor DNA sample; 2, healthy mucosa tissue DNA sample; and 3, peripheral blood DNA sample. MLH1, mutL homolog 1; PMS2, postmeiotic segregation increased 2;HRM, high-resolution melting.](OL-09-01-0183-g00){#f1-ol-09-01-0183}

###### 

Characteristics of the study population.

  Characteristic                                      CRC cases (n=1095)   Control group I, CFCC (n=688)   Control group II, HBDV (n=781)   All controls (n=1469)   OR      95% CI         P-value[a](#tfn1-ol-09-01-0183){ref-type="table-fn"}
  --------------------------------------------------- -------------------- ------------------------------- -------------------------------- ----------------------- ------- -------------- ------------------------------------------------------
  Tumor localization                                                                                                                                                                       
   Colon                                              725                  \-                              \-                               \-                                             
   Rectum                                             370                  \-                              \-                               \-                                             
  Age (years)                                                                                                                                                                              
   47≤                                                94                   164                             427                              591                     Ref.                   
   48--55                                             208                  145                             277                              422                     3.10    2.36--4.09     ≤0.01
   56--65                                             370                  209                             77                               286                     8.13    6.25--10.66    ≤0.01
   \>65                                               423                  170                             0                                170                     15.37   11.66--20.44   ≤0.01
  Gender                                                                                                                                                                                   
   Female                                             435                  317                             343                              660                     Ref.                   
   Male                                               660                  371                             438                              809                     1.23    1.05--1.45     0.01
  BMI                                                                                                                                                                                      
   23.7≤                                              184                  154                             215                              369                     Ref.                   
   23.7--26.2                                         192                  147                             213                              360                     1.07    0.83--1.37     0.61
   26.3--28.9                                         226                  139                             184                              323                     1.40    1.10--1.79     0.01
   \>28.9                                             222                  172                             157                              329                     1.35    1.06--1.73     0.02
  Smoking history                                                                                                                                                                          
   No                                                 536                  364                             451                              815                     Ref.                   
   Yes[b](#tfn2-ol-09-01-0183){ref-type="table-fn"}   501                  254                             327                              581                     1.31    1.12--1.54     ≤0.01
  Family history of CRC                                                                                                                                                                    
   No                                                 726                  486                             718                              1204                    Ref.                   
   Yes                                                144                  90                              52                               142                     1.68    1.31--2.16     ≤0.01
  Address                                                                                                                                                                                  
   City                                               511                  338                             614                              952                     Ref.                   
   Suburbs                                            128                  118                             53                               171                     1.39    1.08--1.79     0.01
   Countryside                                        242                  157                             112                              270                     1.67    1.36--2.05     ≤0.01
  Education                                                                                                                                                                                
   Basic                                              266                  171                             53                               224                     Ref.                   
   Medium                                             469                  327                             492                              820                     0.48    0.39--0.59     ≤0.01
   High                                               138                  114                             231                              345                     0.34    0.26--0.44     ≤0.01

P-value for comparison of CRC cases and all controls.

Ex-smokers are included into this group.

Basic education, completion of eight years of education at primary and secondary school; medium education, completion of 12 years of education at higher secondary school; high education, completion of 17 years of education at university. In cases where categories do not equal 100%, this is due to missing data. CRC, colorectal cancer; CFCC, cancer-free colonoscopy inspected controls; HBDV, healthy blood donor volunteers; OR, odds ratio, CI, confidence interval; BMI, body mass index.
